
    
      The primary study objective is to assess the efficacy of G-ER dosed at 1800mg daily (600mg
      AM, 1200mg PM), compared to placebo in reducing the average daily frequency and severity
      score of moderate to severe hot flashes in postmenopausal women at weeks 4 & 12 of the
      efficacy treatment period, compared with baseline.
    
  